The French Competition Authority fines laboratory for preventing entry of generics in the market for anesthetic drug (Abott France)

Press release published on the official website of the French Competition Authority.

Abbott France abused the dominant position it held in the market for Isoflurane* In a decision dated 10th May 2001, following a referral by the Delegate Minister of Finance and External Trade, the Conseil de la concurrence ruled that the laboratory Abbott France had abused the dominant position it held in 1993 and 1994 in the market for Isoflurane, an anaesthetic. The

Access to this article is restricted to subscribers

Already Subscribed? Sign-in

Access to this article is restricted to subscribers.

Read one article for free

Sign-up to read this article for free and discover our services.

 

PDF Version

Author

Quotation

French Competition Authority, The French Competition Authority fines laboratory for preventing entry of generics in the market for anesthetic drug (Abott France), 10 May 2001, e-Competitions Bulletin Pharma & Dominance, Art. N° 63281

Visites 50

All issues

  • Latest News issue 
  • All News issues
  • Latest Special issue 
  • All Special issues